Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | F2 | P00734 | 2/20 | 0.56 |
| ▸ | F10 | P00742 | 2/20 | 0.56 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | MTTP | P55157 | 1/20 | 0.50 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.48 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4793272 | 0.97 | KMT2A (0.56) | MEN1KMT2AF2F10PRSS1 | |
| SCHEMBL12168558 | 0.85 | MEN1 (0.68) | MEN1KMT2AF2F10PRSS1 | |
| SCHEMBL12168556 | 0.84 | CA12 (0.61) | MEN1KMT2AF2F10PRSS1 | |
| SCHEMBL24304020 | 0.81 | KMT2A (0.54) | MEN1KMT2AF2F10PRSS1 | |
| SCHEMBL30475545 | 0.80 | CTSL (0.48) | MEN1KMT2AF2F10PRSS1 | |
| SCHEMBL23715929 | 0.80 | KMT2A (0.56) | MEN1KMT2APKMGPR88GAA | |
| SCHEMBL29527526 | 0.80 | CTSS (0.73) | MEN1KMT2AF2F10PRSS1 | |
| SCHEMBL6225123 | 0.79 | F2 (0.50) | MEN1KMT2AF2F10PRSS1 | |
| SCHEMBL6184348 | 0.79 | CTSS (0.68) | — | |
| SCHEMBL19471121 | 0.79 | CTSS (0.50) | MEN1KMT2AF2F10PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4342473-A2 | COMPOUNDS USEFUL IN HIV THERAPY | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2024-03-27 | — | — | EP | disclosed |
| US-20240051972-A1 | Compounds Useful in HIV Therapy | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-02-15 | — | — | US | disclosed |
| US-11873310-B2 | Compounds useful in HIV therapy | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-01-16 | — | — | US | disclosed |
| US-11492361-B2 | Compounds useful in HIV therapy | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-11-08 | — | — | US | disclosed |
| US-20220119417-A1 | Compounds Useful in HIV Therapy | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-04-21 | — | — | US | disclosed |
| EP-3886987-A1 | COMPOUNDS USEFUL IN HIV THERAPY | GlaxoSmithKline Intellectual Property Development Ltd (GB) | 2021-10-06 | — | — | EP | disclosed |
| US-20210009609-A1 | Compounds Useful in HIV Therapy | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-01-14 | — | — | US | disclosed |
| US-10870663-B2 | Compounds useful in HIV therapy | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-12-22 | — | — | US | disclosed |
| US-20200299309-A1 | Compounds Useful in HIV Therapy | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-09-24 | — | — | US | disclosed |
| WO-2020110056-A1 | COMPOUNDS USEFUL IN HIV THERAPY | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119417-A1 | Compounds Useful in HIV Therapy | CD4, CCR5, ABCB1 | MEN1 3875/4885KMT2A 4288/4885F2 1434/4885 |
| US-20240051972-A1 | Compounds Useful in HIV Therapy | CD4, CCR5, ABCB1 | MEN1 3875/4885KMT2A 4288/4885F2 1434/4885 |
| US-11873310-B2 | Compounds useful in HIV therapy | CD4, CCR5, ABCB1 | MEN1 3875/4885KMT2A 4288/4885F2 1434/4885 |
| US-10870663-B2 | Compounds useful in HIV therapy | CCR5, SLC11A2, CD4 | MEN1 3938/4885KMT2A 2588/4885F2 2403/4885 |
| US-11492361-B2 | Compounds useful in HIV therapy | CD4, CCR5, ABCB1 | MEN1 3640/4885KMT2A 3866/4885F2 1482/4885 |
| US-20200299309-A1 | Compounds Useful in HIV Therapy | CCR5, SLC11A2, CD4 | MEN1 3938/4885KMT2A 2588/4885F2 2403/4885 |
| US-20210009609-A1 | Compounds Useful in HIV Therapy | CD4, CCR5, ABCB1 | MEN1 3640/4885KMT2A 3866/4885F2 1482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.